Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
about
High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis?Synthetic therapeutic gene circuits in mammalian cellsStructure and function of biotin-dependent carboxylasesRegulation of brown adipocyte metabolism by myostatin/follistatin signalingCurrent and emerging medications for overweight or obesity in people with comorbiditiesA dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty ratFarnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulationFollistatin promotes adipocyte differentiation, browning, and energy metabolismThe Association between Breakfast Skipping and Body Weight, Nutrient Intake, and Metabolic Measures among Participants with Metabolic Syndrome.Synthesis, characterization, and preclinical evaluation of new thiazolidin-4-ones substituted with p-chlorophenoxy acetic acid and clofibric acid against insulin resistance and metabolic disorderInvolvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains.Novel 2,5-disubstituted-1,3,4-oxadiazoles as anti-inflammatory drugs.Novel KIF6 polymorphism increases susceptibility to type 2 diabetes mellitus and coronary heart disease in Han Chinese menEffect of Hypericum perforatum L. extract on insulin resistance and lipid metabolic disorder in high-fat-diet induced obese miceRandomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methodsSirtuin 1 in lipid metabolism and obesity.Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic SteatosisMetabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factorApolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery diseaseThe metabolic syndrome: what's in a name?Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humansTocotrienols reverse cardiovascular, metabolic and liver changes in high carbohydrate, high fat diet-fed rats.Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular diseasePharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.Relationship between Metabolic Syndrome and History of Cervical Cancer among a US National PopulationDisruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.Genetic forms of the cardiometabolic syndrome: what can they tell the clinician?What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.Psoriasis comorbidities.Targeted estrogen delivery reverses the metabolic syndrome.Adipose tissue and metabolic syndrome: too much, too little or neither.The metabolic syndrome: definition, global impact, and pathophysiology.Novel 4-Thiazolidinone Derivatives as Anti-Infective Agents: Synthesis, Characterization, and Antimicrobial EvaluationA Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.Overnutrition, ectopic lipid and the metabolic syndrome.The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation.Is there any association of apolipoprotein E gene polymorphisms with metabolic syndrome in a young population of Croatian origin?
P2860
Q26800733-8C69C2C8-AC8B-4D36-A7C2-60507AAF450BQ26826954-CC246871-3E36-4C41-9882-24AD3C5946E8Q26851762-586767E2-4F33-4C66-BEBD-7A10C5D0AC82Q26863660-8E9F2AF8-20BC-4EEC-99B6-6335D1ED2FE5Q28080825-4E45695D-0F83-4DDA-AA27-29B2146BFD79Q28390006-323B4CAD-0474-43EB-93FF-EB35192418C3Q28581627-A39815DC-DC60-49FE-A6F3-DB937229C8C6Q30572723-9BF594B7-C3A8-4CDA-B764-0A0F2FADB1F8Q33616869-54352052-2FE6-4854-A1CD-FDB1B64CDA55Q33786812-A6AD6582-8A21-467D-9AE7-1D954B56A8C0Q34025180-2BEC2A98-4A73-483D-A366-5B33D5938C0FQ34055370-06116F6C-E123-44B3-921A-043AE97EDE87Q34247656-6DDF82BF-C0FB-47C5-A7A8-CBCA769DF0A6Q34979907-457E81A9-3954-4ED5-A541-A47ED668A842Q35004422-8AB58294-B911-4594-87EF-FBF29D44E6D2Q35141411-2A0FC082-4428-4073-AD68-E383413B738CQ35214969-4E43FE37-2C4E-45D9-BAE9-FCDFDDC60BF9Q35783538-399E53AF-F5E6-4842-BC49-95A0D5FC5CCEQ35935026-D0079BE6-FA1B-4ED2-8131-595ED8F72E48Q36023835-8B95B919-096C-48BB-888B-8C28E6AC04C7Q36329919-2AF475FB-1594-49E2-8700-37E63335F15BQ36329929-6C0C72C8-F86F-417E-8E54-2CC0C291CD64Q36392977-35E95AC2-0A3C-4E0A-9D5A-C9C77ED793C7Q36395774-9E63219E-CCF4-4F51-AAEE-1768AC8901D3Q36493730-B6AB1133-BDBD-485D-B419-3CF66F87E607Q36512376-5CB2EDFF-3529-4EEB-84CD-0CFCEA45E0AEQ36584268-6C7E8EC0-0F16-48DD-BD9A-8EEBB4B573C3Q36644432-38ED66F1-E5EF-4ED9-A7B7-D654DBF78884Q36904431-198CF406-9E97-4856-9024-9FDB50DE1110Q36932044-12A8047D-050E-4B9E-B823-DB3E05964285Q36966063-ABD6495B-06FF-43B2-B846-1697A2F48D8CQ37084274-678C1D32-89A7-431E-A423-77BDBCEEE568Q37134063-62FB2F62-A735-415E-B1FF-2ECAFF07C565Q37308618-F67AF158-C036-4D39-AC15-1ED44C1F0509Q37617790-1830D5AA-977C-4EE0-AFAA-90BCEF8F18A2Q38295238-C4FEA82B-780E-4DEA-AAD4-ADD535AC4729Q38718299-4E1C6B83-EE58-436C-AFBD-3EF3EC563B42Q38838126-C860D006-EEB0-4CA1-AE8C-A55ECA932FA8Q39597767-C2439FA2-2266-439A-872D-4B27290B4802Q40662832-34F4DF42-D642-4096-BA40-7681D9C87ED0
P2860
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@ast
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@en
type
label
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@ast
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@en
prefLabel
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@ast
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@en
P2860
P356
P1476
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
@en
P2093
Scott M Grundy
P2860
P2888
P304
P356
10.1038/NRD2005
P577
2006-04-01T00:00:00Z